Trump Rebrands Biden’s Drug Reforms as His Own
President Donald Trump this week unveiled sweeping “Most Favored Nation” drug pricing agreements with nine pharmaceutical companies, promising Americans unprecedented discounts on insulin, cancer treatments, and other life‑saving medicines. For millions of families struggling under the weight of prescription costs, the announcement sounded like long‑awaited relief. But policy experts say much of what is being promoted under Trump’s “TrumpRx” program closely mirrors reforms enacted under President Joe Biden, raising concerns about whether the public is being misled about who delivered the underlying changes. The White House highlighted dramatic examples of price reductions, including Plavix dropping from $756 to $16, Epclusa … Continue reading Trump Rebrands Biden’s Drug Reforms as His Own

